The Future of Biomanufacturing | Michael Heltzen, eXoZymes

What It Covers

Michael Heltzen, CEO of eXoZymes (Nasdaq), explains how his company manufactures complex natural compounds using cell-free enzymatic pathways combined with AI-driven protein engineering, with a lead product targeting metabolic health as both a nutraceutical and pharmaceutical candidate.

Key Questions Answered

• •Cell-Free Manufacturing Advantage: Traditional synthetic biology fails at scale because living cells actively resist overproduction, become toxic when pushed, and trap end products inside cellular material — making isolation costs exceed product value. eXoZymes removes the cell entirely, running enzymatic pathways as controlled biochemical reactions that perform equally well or better at larger production volumes.
• •NCT Metabolic Compound: eXoZymes' flagship molecule NCT activates mitochondrial activity to convert fat into energy, targeting a different mechanism than GLP-1 drugs, which suppress hunger signals. NCT exists naturally in black pepper but only in trace amounts — requiring an impractical volume of raw material per dose — making cell-free biosynthesis the only viable production route.
• •Brute-Force Evolution via AI: eXoZymes uses protein folding models to predict roughly 1,000 enzyme mutations per cycle, then builds and performance-tests all variants simultaneously using cell-free protein synthesis — no cell culturing required. Results feed back into the algorithm as reinforcement training, compressing billions of years of natural evolutionary iteration into approximately one week of lab work.
• •Cross-Kingdom Enzyme Substitution: When optimizing a biosynthetic pathway, eXoZymes identifies the specific chemical reaction causing a bottleneck, then searches entirely different biological kingdoms for an enzyme performing that same reaction. That enzyme is extracted, optimized into an "exozyme," and plugged into the pathway — treating biochemistry as modular, interchangeable chemistry rather than organism-specific biology.
• •Dual-Track Commercialization Strategy: eXoZymes pursues NCT simultaneously as an over-the-counter nutraceutical supplement and as a pharmaceutical candidate via licensing or venture partnerships with biotech or pharma companies. Two additional products are already in development, with a structured screening process evaluating candidates on market size, competitive landscape, and platform fit before committing resources.